A citation-based method for searching scientific literature

Mads Ersbøll, Mikkel Jürgens, Philip Hasbak, Andreas Kjær, Emil Wolsk, Bo Zerahn, Niels H Brandt-Jacobsen, Peter Gæde, Peter Rossing, Jens Faber, Silvio E Inzucchi, Finn Gustafsson, Morten Schou, Caroline Kistorp. Int J Cardiovasc Imaging 2022
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
Massar Omar, Jesper Jensen, Mulham Ali, Peter H Frederiksen, Caroline Kistorp, Lars Videbæk, Mikael Kjær Poulsen, Christian D Tuxen, Sören Möller, Finn Gustafsson,[...]. JAMA Cardiol 2021
30
100


Imaging, Biomarker, and Clinical Predictors of Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction.
Alberto Aimo, Hanna K Gaggin, Andrea Barison, Michele Emdin, James L Januzzi. JACC Heart Fail 2019
48
100

Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging.
Jens-Uwe Voigt, Gianni Pedrizzetti, Peter Lysyansky, Tom H Marwick, Helen Houle, Rolf Baumann, Stefano Pedri, Yasuhiro Ito, Yasuhiko Abe, Stephen Metz,[...]. Eur Heart J Cardiovasc Imaging 2015
531
100

Reproducibility of regional and global longitudinal strains derived from two-dimensional speckle-tracking and doppler tissue imaging between expert and novice readers during quantitative dobutamine stress echocardiography.
Akira Yamada, Sushil A Luis, Daniel Sathianathan, Bijoy K Khandheria, James Cafaro, Christian R Hamilton-Craig, David G Platts, Luke Haseler, Darryl Burstow, Jonathan Chan. J Am Soc Echocardiogr 2014
40
100

Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial.
Jagdeep S S Singh, Ify R Mordi, Keeran Vickneson, Amir Fathi, Peter T Donnan, Mohapradeep Mohan, Anna Maria J Choy, Stephen Gandy, Jacob George, Faisel Khan,[...]. Diabetes Care 2020
51
100

Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.
Carlos G Santos-Gallego, Juan Antonio Requena-Ibanez, Rodolfo San Antonio, Kiyotake Ishikawa, Shin Watanabe, Belen Picatoste, Eduardo Flores, Alvaro Garcia-Ropero, Javier Sanz, Roger J Hajjar,[...]. J Am Coll Cardiol 2019
211
100

Head-to-Head Comparison of Global Longitudinal Strain Measurements among Nine Different Vendors: The EACVI/ASE Inter-Vendor Comparison Study.
Konstantinos E Farsalinos, Ana M Daraban, Serkan Ünlü, James D Thomas, Luigi P Badano, Jens-Uwe Voigt. J Am Soc Echocardiogr 2015
379
100

2021 ESC/EACTS Guidelines for the management of valvular heart disease.
Alec Vahanian, Friedhelm Beyersdorf, Fabien Praz, Milan Milojevic, Stephan Baldus, Johann Bauersachs, Davide Capodanno, Lenard Conradi, Michele De Bonis, Ruggero De Paulis,[...]. Eur Heart J 2022
236
100

CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Ele Ferrannini, Michael Mark, Eric Mayoux. Diabetes Care 2016
559
100

Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).
Jesper Jensen, Massar Omar, Caroline Kistorp, Mikael Kjær Poulsen, Christian Tuxen, Ida Gustafsson, Lars Køber, Finn Gustafsson, Emil Fosbøl, Niels Eske Bruun,[...]. Trials 2019
24
100

Prognostic Value of Global Longitudinal Strain-Based Left Ventricular Contractile Reserve in Candidates for Percutaneous Correction of Functional Mitral Regurgitation: Implications for Patient Selection.
Antonio De Luca, Davide Stolfo, Thomas Caiffa, Renata Korcova, Giulia Barbati, Giancarlo Vitrella, Serena Rakar, Andrea Perkan, Gabriele Secoli, Bruno Pinamonti,[...]. J Am Soc Echocardiogr 2019
5
100

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
100

Can activity monitors predict outcomes in patients with heart failure? A systematic review.
Matthew K H Tan, Joanna K L Wong, Kishan Bakrania, Yusuf Abdullahi, Leanne Harling, Roberto Casula, Alex V Rowlands, Thanos Athanasiou, Omar A Jarral. Eur Heart J Qual Care Clin Outcomes 2019
11
100


Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
100

Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction.
Massar Omar, Jesper Jensen, Peter H Frederiksen, Caroline Kistorp, Lars Videbæk, Mikael Kjær Poulsen, Sören Möller, Mulham Ali, Finn Gustafsson, Lars Køber,[...]. J Am Coll Cardiol 2020
26
100

Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study.
Juan Antonio Requena-Ibáñez, Carlos G Santos-Gallego, Anderly Rodriguez-Cordero, Ariana P Vargas-Delgado, Donna Mancini, Samantha Sartori, Farah Atallah-Lajam, Chiara Giannarelli, Frank Macaluso, Anuradha Lala,[...]. JACC Heart Fail 2021
25
100

Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients.
Roni Nielsen, Niels Møller, Lars C Gormsen, Lars Poulsen Tolbod, Nils Henrik Hansson, Jens Sorensen, Hendrik Johannes Harms, Jørgen Frøkiær, Hans Eiskjaer, Nichlas Riise Jespersen,[...]. Circulation 2019
133
100

Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
Salva R Yurista, Herman H W Silljé, Silke U Oberdorf-Maass, Elisabeth-Maria Schouten, Mario G Pavez Giani, Jan-Luuk Hillebrands, Harry van Goor, Dirk J van Veldhuisen, Rudolf A de Boer, B Daan Westenbrink. Eur J Heart Fail 2019
131
100

Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic).
Jesper Jensen, Massar Omar, Caroline Kistorp, Christian Tuxen, Ida Gustafsson, Lars Køber, Finn Gustafsson, Jens Faber, Julie L Forman, Jacob E Møller,[...]. Circulation 2021
3
100

Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
Matthew M Y Lee, Katriona J M Brooksbank, Kirsty Wetherall, Kenneth Mangion, Giles Roditi, Ross T Campbell, Colin Berry, Victor Chong, Liz Coyle, Kieran F Docherty,[...]. Circulation 2021
98
100

Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Akshay S Desai, Scott D Solomon, Amil M Shah, Brian L Claggett, James C Fang, Joseph Izzo, Kevin McCague, Cheryl A Abbas, Ricardo Rocha, Gary F Mitchell. JAMA 2019
120
100

Multidimensional contractile reserve predicts adverse outcome in patients with severe systolic heart failure: a 4-year follow-up study.
Ioannis A Paraskevaidis, Ignatios Ikonomidis, Panagiotis Simitsis, John Parissis, Vasilios Stasinos, George Makavos, John Lekakis. Eur J Heart Fail 2017
17
100

The importance of myocardial contractile reserve in predicting response to cardiac resynchronization therapy.
Mariëlle Kloosterman, Kevin Damman, Dirk J Van Veldhuisen, Michiel Rienstra, Alexander H Maass. Eur J Heart Fail 2017
18
100

Myocardial contractile reserve during exercise predicts left ventricular reverse remodelling after cardiac resynchronization therapy.
Patrizio Lancellotti, Mario Senechal, Marie Moonen, Erwan Donal, Julien Magne, Eric Nellessen, Emilio Attena, Bernard Cosyns, Pierre Melon, Luc Piérard. Eur J Echocardiogr 2009
29
100

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits.
Antonius Baartscheer, Cees A Schumacher, Rob C I Wüst, Jan W T Fiolet, Ger J M Stienen, Ruben Coronel, Coert J Zuurbier. Diabetologia 2017
303
100

Implications of Altered Ketone Metabolism and Therapeutic Ketosis in Heart Failure.
Senthil Selvaraj, Daniel P Kelly, Kenneth B Margulies. Circulation 2020
44
100

Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Faiez Zannad. JAMA Cardiol 2017
203
100

Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy.
Julio A Panza, Alicia M Ellis, Hussein R Al-Khalidi, Thomas A Holly, Daniel S Berman, Jae K Oh, Gerald M Pohost, George Sopko, Lukasz Chrzanowski, Daniel B Mark,[...]. N Engl J Med 2019
88
100

Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial.
Jesper Jensen, Massar Omar, Caroline Kistorp, Mikael Kjær Poulsen, Christian Tuxen, Ida Gustafsson, Lars Køber, Finn Gustafsson, Jens Faber, Emil L Fosbøl,[...]. Am Heart J 2020
29
100

Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.
Jesper Jensen, Massar Omar, Caroline Kistorp, Christian Tuxen, Ida Gustafsson, Lars Køber, Finn Gustafsson, Jens Faber, Mariam Elmegaard Malik, Emil Loldrup Fosbøl,[...]. Lancet Diabetes Endocrinol 2021
39
100

Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
Carlos G Santos-Gallego, Ariana P Vargas-Delgado, Juan Antonio Requena-Ibanez, Alvaro Garcia-Ropero, Donna Mancini, Sean Pinney, Frank Macaluso, Samantha Sartori, Merce Roque, Fernando Sabatel-Perez,[...]. J Am Coll Cardiol 2021
106
100

Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Subodh Verma, C David Mazer, Andrew T Yan, Tamique Mason, Vinay Garg, Hwee Teoh, Fei Zuo, Adrian Quan, Michael E Farkouh, David H Fitchett,[...]. Circulation 2019
215
100

SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial.
Katrine M Lauritsen, Bent R R Nielsen, Lars P Tolbod, Mogens Johannsen, Jakob Hansen, Troels K Hansen, Henrik Wiggers, Niels Møller, Lars C Gormsen, Esben Søndergaard. Diabetes 2021
16
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.